orforglipron and retatrutide Eli Lilly Company's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Lilly's Orforglipron, Retatrutide Named as

Other Possible Serious or Concerning Side Effects Although rare, some studies have reported more serious or unusual adverse events, including: Cardiac arrhythmia Elevated liver enzymes Acute pancreatitis (rare cases) Abnormal skin sensations (dysesthesia) in some trials Because the drug affects several hormone pathways involved in metabolism, researchers say long-term safety data will be essential before approval

2024 Jun 26;13(13):3729)

KOH Test or Skin Scraping Sometimes the doctor may gently scrape a small sample of skin from the infected area and send it for laboratory testing

AbdelnabyEAEmamIASalemNYRamadanESKhattabMSFarghaliHAet al

Isoprenaline via cAMP and the cAMP-dependent protein kinase phosphorylates thereby increases the open probability of the L-type calcium channel (Fig